Logo image of ZLAB

ZAI LAB LTD-ADR (ZLAB) Stock Fundamental Analysis

NASDAQ:ZLAB - Nasdaq - US98887Q1040 - ADR - Currency: USD

30.14  -1.17 (-3.74%)

After market: 30.16 +0.02 (+0.07%)

Fundamental Rating

3

Overall ZLAB gets a fundamental rating of 3 out of 10. We evaluated ZLAB against 558 industry peers in the Biotechnology industry. Both the profitability and financial health of ZLAB have multiple concerns. ZLAB shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ZLAB has reported negative net income.
ZLAB had a negative operating cash flow in the past year.
ZLAB had negative earnings in each of the past 5 years.
ZLAB had a negative operating cash flow in each of the past 5 years.
ZLAB Yearly Net Income VS EBIT VS OCF VS FCFZLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

ZLAB has a better Return On Assets (-21.48%) than 77.68% of its industry peers.
The Return On Equity of ZLAB (-31.09%) is better than 76.43% of its industry peers.
Industry RankSector Rank
ROA -21.48%
ROE -31.09%
ROIC N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ZLAB Yearly ROA, ROE, ROICZLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

With a decent Gross Margin value of 63.62%, ZLAB is doing good in the industry, outperforming 79.64% of the companies in the same industry.
ZLAB's Gross Margin has declined in the last couple of years.
ZLAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
ZLAB Yearly Profit, Operating, Gross MarginsZLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K

More info and screens

3

2. Health

2.1 Basic Checks

ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZLAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ZLAB has been increased compared to 5 years ago.
Compared to 1 year ago, ZLAB has a worse debt to assets ratio.
ZLAB Yearly Shares OutstandingZLAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ZLAB Yearly Total Debt VS Total AssetsZLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.83 indicates that ZLAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.83, ZLAB is doing good in the industry, outperforming 75.18% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that ZLAB is not too dependend on debt financing.
ZLAB has a Debt to Equity ratio of 0.21. This is in the lower half of the industry: ZLAB underperforms 70.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 2.83
ROIC/WACCN/A
WACC7.93%
ZLAB Yearly LT Debt VS Equity VS FCFZLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ZLAB has a Current Ratio of 3.26. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.26, ZLAB is not doing good in the industry: 63.04% of the companies in the same industry are doing better.
A Quick Ratio of 3.09 indicates that ZLAB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.09, ZLAB is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 3.09
ZLAB Yearly Current Assets VS Current LiabilitesZLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.43% over the past year.
Looking at the last year, ZLAB shows a very strong growth in Revenue. The Revenue has grown by 43.72%.
ZLAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.34% yearly.
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%22.19%

3.2 Future

Based on estimates for the next years, ZLAB will show a very strong growth in Earnings Per Share. The EPS will grow by 91.89% on average per year.
ZLAB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.53% yearly.
EPS Next Y41.13%
EPS Next 2Y45.88%
EPS Next 3Y53.48%
EPS Next 5Y91.89%
Revenue Next Year45.3%
Revenue Next 2Y47.2%
Revenue Next 3Y46.43%
Revenue Next 5Y40.53%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ZLAB Yearly Revenue VS EstimatesZLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
ZLAB Yearly EPS VS EstimatesZLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 60 80

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZLAB. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 95.37, which means the current valuation is very expensive for ZLAB.
Based on the Price/Forward Earnings ratio, ZLAB is valued cheaply inside the industry as 88.57% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.15. ZLAB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 95.37
ZLAB Price Earnings VS Forward Price EarningsZLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLAB Per share dataZLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ZLAB's earnings are expected to grow with 53.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.88%
EPS Next 3Y53.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZLAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZAI LAB LTD-ADR

NASDAQ:ZLAB (5/30/2025, 8:00:02 PM)

After market: 30.16 +0.02 (+0.07%)

30.14

-1.17 (-3.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/dmh
Earnings (Next)08-04 2025-08-04
Inst Owners46.34%
Inst Owner Change-1.63%
Ins Owners1.42%
Ins Owner Change-27.54%
Market Cap3.30B
Analysts78.46
Price Target33.31 (10.52%)
Short Float %6.63%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.76%
Min EPS beat(2)-12.04%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)15.62%
Min EPS beat(4)-12.04%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)14.36%
EPS beat(12)9
Avg EPS beat(12)39.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.12%
Min Revenue beat(2)-10.58%
Max Revenue beat(2)-1.65%
Revenue beat(4)1
Avg Revenue beat(4)-2.51%
Min Revenue beat(4)-10.58%
Max Revenue beat(4)4.31%
Revenue beat(8)3
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.95%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.32%
PT rev (3m)12.98%
EPS NQ rev (1m)15.81%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.23%
EPS NY rev (3m)14.68%
Revenue NQ rev (1m)-3.49%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 95.37
P/S 7.9
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 4.4
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)0.32
Fwd EY1.05%
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS3.82
BVpS7.39
TBVpS6.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.48%
ROE -31.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.62%
FCFM N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 425.79%
Cap/Sales 12.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 3.09
Altman-Z 2.83
F-Score5
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y41.13%
EPS Next 2Y45.88%
EPS Next 3Y53.48%
EPS Next 5Y91.89%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%22.19%
Revenue Next Year45.3%
Revenue Next 2Y47.2%
Revenue Next 3Y46.43%
Revenue Next 5Y40.53%
EBIT growth 1Y29.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.05%
EBIT Next 3Y36.62%
EBIT Next 5Y32.27%
FCF growth 1Y35.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.69%
OCF growth 3YN/A
OCF growth 5YN/A